BioSpace News Archive

Training session curriculums and schedules have been announced for Analytics Summit 2019 presented by the University of Cincinnati Center for Business Analytics.

Aradigm Corporation has filed for protection under Chapter 11 of the U.S. Bankruptcy Code in the Alameda County Court District to facilitate the sale of its assets.

Healthline Media announced that it has acquired Greatist.com, a healthy living and fitness property aimed primarily at 18 – 35 year olds.

Polygon Company, a leading producer of composite tubing, bearings, and cylinders, announces high-performance PolyMed® Composite Tubing for surgical applications

Myriad Genetics, Inc. (NASDAQ: MYGN), a global leader in personalized medicine, today announced its support of the American Society of Breast Surgeons (ASBrS) new guidelines that recommend all people diagnosed with breast cancer undergo genetic testing with a multi-gene panel.

Polarean Imaging plc (AIM: POLX), the medical imaging technology company, with a proprietary drug device combination product for the magnetic resonance imaging (MRI) market, announces that it has entered into a contract for the procurement of its latest polarizer system by the University of British Columbia www.ubc.ca (“UBC”) following the conclusion of UBC’s procurement process.

UK based SkinBioTherapeutics is developing a range of scientifically validated treatments derived from probiotic bacteria for use in cosmetics, infection control products and for the treatment of eczema

Sygnature Discovery, the leading independent integrated drug discovery and pre-clinical services provider, have made two key appointments. Dr Allan Jordan and Ms Louisa Jordison have joined the organisation as they continue their strong growth trajectory in the drug research market.

Michael E. Jung, distinguished professor of chemistry and biochemistry at UCLA, was honored for his significant contributions to biomedicine during a Cal State LA BioSpace ceremony celebrating emerging entrepreneurs.

Novus Therapeutics, Inc. (“Novus”) is a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat (“ENT”).